cytarabine/daunorubicin; CPX-351 (Vyxeos)

Indications

• treatment-related acute myeloid leukemia
• myelodysplasia-related acute myeloid leukemia

Adverse effects

• hemorrhage
• febrile neutropenia, bacteremia, chills
• rash, edema, mucositis
• nausea, vomiting, diarrhea, constipation
• musculoskeletal pain, abdominal pain, headache
• cough, dyspnea, pneumonia
• fatigue, decreased appetite, sleep disorders
• arrhythmias

Notes

• CPX-351 (Vyxeos) is a liposomal formulation of cytarabine & daunorubicin

More general terms

• antineoplastic combination (combination chemotherapy)

Components

• cytosine arabinoside; cytarabine (Cytosar, ARA-C, HiDAC, Depocyt)
• daunorubicin, daunomycin; DNR (Cerubidine, DaunoXome)